Chuikyo Debate on FY2026 Drug Pricing Reform

• FIRM Calls for Pricing Overhaul to Reflect Unique Benefits of Regenerative Therapies
  September 18, 2025

• FPMAJ Urges Blanket Drug Price Hikes to Offset Inflation: FY2026 Reform Talks
  September 18, 2025

• Tensions Flare at Chuikyo over Premiums for Generic Dispensing
  September 16, 2025

• Japan to Discuss Negative Margins, Packaging Optimization towards FY2026 Reform
  August 8, 2025

• Medical Device Pricing Body Urges Clearer Evaluation Criteria for SaMDs Reimbursement
  August 8, 2025

• Industry Urges “Objective Review First” for CEA Reform; Payers Push for Expansion
  August 7, 2025

• DPO Floats Premium Expansion, Relaxed Criteria towards FY2026 Reform
  August 7, 2025

• Japan Begins FY2026 CEA Reform Talks, Re-Designation after Market Expansion Up for Debate
  July 17, 2025

• Generic and Wholesaler Groups Call for Pricing Reforms to Reflect Inflationary Pressures
  July 11, 2025

• 16 Drugs Enter Japan Trials after Pro-Innovation Reform: Industry Poll
  July 10, 2025

• Pharma Groups Renew Push for Price Stability During Patent Term as FY2026 Reform Talks Begin
  July 10, 2025

• Trade Groups Urge Pricing Overhaul for Regenerative Medicines, Biotech Drugs
  July 10, 2025

• Japan Begins FY2026 Drug Pricing Reform Talks; Responses to Inflation, High-Cost Therapies on Agenda
  June 26, 2025

• Chuikyo OKs Drug Price Survey Plan for FY2026 Revision
  June 26, 2025

ページ